Oppenheimer raised the firm’s price target on Prothena (PRTA) to $62 from $58 and keeps an Outperform rating on the shares. The firm sees a ...

Recent research from Stony Brook Medicine shows that early signs of dementia are becoming more frequent among first ...

Chiefs Hall of Honor member Art Still is a proud foot soldier in the Amyloidosis Army, a nonprofit he started hoping to ...

Alnylam’s (ALNY) treatment of transthyretin-mediated amyloidosis, or ATTR amyloidosis, was granted FDA orphan designation, according to a post ...

Alnylam Pharmaceuticals (NASDAQ:ALNY), with a market capitalization of $35.4 billion, has emerged as a leading player in the RNA interference (RNAi) therapeutics space, with a particular focus on ...

Insights into the structures could lead to improved treatment strategies for transthyretin amyloidosis, a progressive, fatal disease in men.

The tiny protein known as transthyretin can cause big problems in the body when it misfolds after secretion. While healthy ...

The tiny protein known as transthyretin can cause big problems in the body when it misfolds after secretion. While healthy transthyretin moves hormones through blood and spinal fluid, misfolded ...

Now, Scripps Research scientists have uncovered new structures of transthyretin. Their findings, published in Nature Structural & Molecular Biology on January 22, 2025, show how the three-dimension ...

Intellia downgraded to market perform at Morgan Stanley on concerns for ATTR-CM candidate nexiguran ziclumeran. Read more ...

The tiny protein known as transthyretin can cause big problems in the body when it misfolds after secretion. While healthy transthyretin moves hormones through blood and spinal fluid, misfolded ...

Closing in on 25 years since the World Trade Center (WTC) attacks, WTC responders continue to suffer long-term effects from their exposures at Ground Zero. One issue of possible growing concern is ...